Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $18.00
by Doug Wharley · The Cerbat GemShares of Altimmune, Inc. (NASDAQ:ALT – Get Free Report) have received a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $18.00.
A number of research analysts have recently commented on ALT shares. HC Wainwright increased their price objective on Altimmune from $12.00 to $25.00 and gave the company a “buy” rating in a report on Monday, March 16th. Truist Financial began coverage on Altimmune in a research report on Wednesday, March 18th. They set a “buy” rating and a $12.00 price objective on the stock. William Blair restated a “market perform” rating on shares of Altimmune in a research note on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Friday, March 27th. Finally, Barclays started coverage on Altimmune in a report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 target price on the stock.
Read Our Latest Report on Altimmune
Altimmune Price Performance
ALT stock opened at $3.34 on Thursday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15. Altimmune has a one year low of $2.87 and a one year high of $7.73. The firm has a market capitalization of $434.53 million, a PE ratio of -3.31 and a beta of 0.34. The firm has a 50-day moving average of $4.18 and a two-hundred day moving average of $4.25.
Altimmune (NASDAQ:ALT – Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%. On average, analysts forecast that Altimmune will post -1.35 earnings per share for the current year.
Insiders Place Their Bets
In other news, CEO Jerome Benedict Durso purchased 20,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the transaction, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at approximately $115,050. The trade was a 160.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders bought a total of 30,000 shares of company stock valued at $108,900 over the last quarter. Corporate insiders own 1.60% of the company’s stock.
Institutional Investors Weigh In On Altimmune
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SBI Securities Co. Ltd. lifted its position in Altimmune by 27.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after buying an additional 1,928 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after acquiring an additional 2,241 shares during the period. Concurrent Investment Advisors LLC lifted its stake in shares of Altimmune by 10.4% during the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock worth $96,000 after buying an additional 2,500 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Altimmune by 10.9% during the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock worth $108,000 after acquiring an additional 2,748 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in Altimmune by 4.0% in the 4th quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock valued at $289,000 after purchasing an additional 3,047 shares during the period. 78.05% of the stock is currently owned by institutional investors and hedge funds.
Altimmune Company Profile
Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.
Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.